BUSINESS
Novo Nordisk
BUSINESS
Novo Nordisk woes prompt Denmark to slash country’s 2025 growth forecast
BUSINESS
Wegovy maker Novo Nordisk to reduce costs after US$95bil stock loss
WORLD
US plans Medicare, Medicaid coverage for weight-loss drugs
BUSINESS
Novo Nordisk’s shares extend losses, erasing nearly all gains since Wegovy launch
BUSINESS
Pharma shares slump after Trump price threat
BUSINESS
India’s Biocon aims to lead copycat Wegovy sales in Canada from next year
BUSINESS
Obesity drug maker Novo Nordisk ousts CEO as competition weighs
BUSINESS
Investors seek answers on Novo Nordisk’s next-gen obesity drug CagriSema
BUSINESS
Novo, Lilly shares rise as Biden proposes obesity care coverage
BUSINESS
US Congress calls on Novo Nordisk to lower drug prices
BUSINESS
Novo Nordisk, Indonesia’s Bio Farma sign deal to produce insulin
BUSINESS
Novo, Lilly shares fall after Biden calls for cheaper obesity drugs
BUSINESS
Weight-loss drug forecasts jump to US$150bil as supply grows
BUSINESS
Novo Nordisk raises outlook fuelled by obesity drug demand
BUSINESS
US FDA approves Wegovy for lowering stroke, heart attack risks
BUSINESS
Novo Nordisk eyes China approval for weight loss drug Wegovy
BUSINESS
Novo Nordisk’s Wegovy success spurs cardiovascular disease focus
BUSINESS
Indian pharma joins Wegovy weight-loss craze with generics
BUSINESS
Weight-loss drug maker Novo Nordisk’s profit soars 51%
BUSINESS
Novo Nordisk enters into research tie-ups with US biotech firms
BUSINESS
Counterfeit Novo diabetes drug floods US supply chain
BUSINESS
Novo Nordisk owner invests US$265mil in vaccine research
BUSINESS